Business | |||||||
NEWS | |||||||
The 'least bad' option for fixing New York's traffic woes To live in New York City is to be forever serenaded by an orchestra of honking cars. The Big Apple currently tops the list of the world's most congested urban areas. In 2024, the city's transit authority estimated people lost an average of 117 hours ...
| |||||||
September 2024 US Airline Traffic Data Up 1.6% from the Same Month Last Year U.S. airlines carried 77.5 million systemwide (domestic and international) scheduled service passengers in September 2024, according to the Bureau of Transportation Statistics (BTS). When adjusted for seasonality, September enplanements are down 0.4% from ...
| |||||||
ABI response to FCA Advice Guidance Boundary Review The FCA and the Government are undertaking a joint review to examine the regulatory boundary between financial advice and financial guidance - known as the Advice Guidance Boundary Review. Their goal is to create a regulatory framework that ensures ...
| |||||||
CEC Approves $1.4 Billion Plan to Expand Zero-Emission Transportation Infrastructure For Immediate Release: December 11, 2024. WHAT YOU NEED TO KNOW: California continues to invest an unprecedented amount of funding to build a bigger, better, and more reliable network of electric charging and hydrogen refueling stations, ...
| |||||||
A Greener Christmas is the Best Present for The Environment From reusing items like plastic carrier bags and envelopes, to reducing food waste and choosing products with less packaging, we can all help to make the festive season more sustainable. This year, we are promoting ...
| |||||||
Minister Blair congratulates successful Canadian innovators joining the 2025 NATO DIANA cohort December 12, 2024 – Ottawa, Ontario – National Defence / Canadian Armed Forces. The North Atlantic Treaty Organization's (NATO) Defence Innovation Accelerator for the North Atlantic (DIANA) has announced the successful innovators in 2024's competitive ...
| |||||||
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
| |||||||
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary ... Based on its review of postmarket clinical trial data, the U.S. Food and Drug Administration (FDA) identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did not have ...
| |||||||
See more results | Edit this alert |
You have received this email because you have subscribed to Google Alerts. |
Receive this alert as RSS feed |
Send Feedback |
Tidak ada komentar:
Posting Komentar